Monoclonal gammopathy of undetermined significance (MGUS; ICD-O-3=9761/1) is a premalignant clonal disorder that progresses to myeloma at ~1% per year. Whilst MGUS is often diagnosed incidentally and other symptoms of myeloma are absent, several follow-up studies have reported relationships with co-morbidities and poor survival. Illness patterns before MGUS diagnoses have, however, not been examined in relation to those seen after diagnosis. Here we compare hospital activity of people with MGUS and patients with mature B-cell malignancies to that in the general population.
|Journal||British journal of cancer|
|Early online date||4 Oct 2019|
|Publication status||Published - 28 Oct 2019|
|Event||The National Cancer Research Institute (NCRI) Cancer Conference 2019 - Glasgow, United Kingdom|
Duration: 3 Nov 2019 → 5 Nov 2019
Bibliographical noteIf any changes are made to this PURE entry can you please inform email@example.com
Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute